Repair of conjunctival defects
Conditions
Interventions
Trial group:Acellular conjunctival matrix is used
Control group:Biological amniotic membrane is used
Sponsors
Eye and ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years old, gender unlimited; 2. The conjunctival defect area is not greater than 1/3 of the bulbar conjunctival (pterygium surgery, recurrent pterygium surgery, eyelid adhesion surgery, conjunctival pigmentation nevus or conjunctival mass excision, etc.); 3. If only one eye of the selected cases meets the inclusion criteria, this eye is the experimental eye. If both eyes of the selected cases meet the inclusion criteria, the sicker eye at the time of screening is the test eye. If both eyes have similar conditions, choose the right eye as the test eye; 4. Agree and sign informed consent, cooperate with treatment and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with serious blood diseases and history; 2. Severe dry eye, Schirmer test =8.0mmol/L; 12. Have a malignant tumor; 13. Patients with blepharon adhesion had quiet lesions for less than 3 months and had inflammatory reactions; 14. Received clinical trials of other drugs or medical devices within 3 months; 15. Participants considered unsuitable for this clinical trial by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The healing efficiency of the surface epithelium of the graft 10 days after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pterygium recurrence rates at 90 and 180 days after surgery;The healing efficiency of graft surface epithelium was observed at 3, 5 and 7 days after operation;Postoperative ocular irritation;Postoperative wound hyperemia;Postoperative blepharon adhesion; | — |
Countries
China
Contacts
Public ContactJianjiang Xu
Eye and ENT Hospital of Fudan University
Outcome results
None listed